The physiological and clinical importance of sodium potassium ATPase in cardiovascular diseases

Yanling Yan and Joseph I Shapiro

CrossMark

The Na/K-ATPase has been extensively studied, but it is only recently that its role as a scaffolding and signaling protein has been identified. It has been identified that cardiotonic steroids (CTS) such as digitalis mediate signal transduction through the Na/K-ATPase in a process found to result in the generation of reactive oxygen species (ROS). As these ROS also appear capable of initiating this signal cascade, a feed forward amplification process has been postulated and subsequently implicated in some disease pathways including uremic cardiomyopathy.

Address
Joan C. Edwards School of Medicine, Marshall University, Department of Medicine, USA

Corresponding author: Shapiro, Joseph I (shapiroj@marshall.edu)

Introduction

The Na/K-ATPase enzyme (EC 3.6.3.9.), or 'sodium pump' was first identified by Skou on the crab nerve in 1957 [1]. Besides its transportation of ions, in the late 1990s, Dr. Zijian Xie and our research group discovered a scaffolding and signaling function for the Na/K-ATPase, where the Na/K-ATPase/Src complex acts as a unique receptor for cardiotonic steroids (CTS). This signaling pathway appears to be involved a number of clinical disorders including cardiovascular diseases and hypertension, salt balance, renal diseases, diabetes and other metabolic diseases, as well as neurological disorders [2,3]. Moreover, the alteration of signaling receptor function is also seen in hypertension, cardiac hypertrophy, ischemia/reperfusion injury, cancer, and tissue fibrosis. Therefore, this enzyme assumes an increasing importance for researchers and clinicians [4].

Structure and pumping function of the Na/K-ATPase

Structurally, Na/K-ATPase primarily consists of three subunits denoted by α, β, and γ, with only the α and β subunits necessary for ion pumping. The catalytic α subunit contains binding sites for the cations (Na^+ and K^+), ATP and cardiotonic steroids (CTS) such as ouabain [5]. The β subunit is also essential for pump function, and it appears to stabilize the α subunit conformation as well as chaperone the delivery of the α/β complex to the plasma membrane. In some tissues, a third subunit, γ subunit (FXYD protein) may help to regulate sodium pump activity [6,7]. The Na/K-ATPase α subunit with 11 transmembrane domains has 4 isoforms. The α1 isoform is found in all cells, α2 and α3 isoforms are mainly expressed in skeletal muscle, neuronal tissue, and cardiac myocytes. The α4 isoform is in testis and regulates sperm motility.

The structure–function relationships in Na/K-ATPase were extensively studied in the later portions of the 20th century and has received new attention due to the recently recognized Na/K-ATPase scaffolding and signaling functions which we will discuss further [8•,9]. The alteration between two major conformational states is responsible for pumping of ions. In E1 (Na^+-form), the cation-binding sites have high affinity for Na^+ and face the cytoplasm. In E2 (K^+-form), the cation-binding sites have high affinity for K and face the extracellular side [9,10]. Functionally, the Na/K-ATPase α subunit has 3 cytoplasmic A (actuator), N (nucleotide binding) and P (phosphorylation) domains. During the ion pumping cycle, the relative positions of these domains change as they also do in response to binding CTS [10].

Third factor

It was clear to renal physiologists and nephrologists that changes in glomerular filtration rate (factor 1) and mineralocorticoids (factor 2) could not explain natriuretic responses to acute or chronic expansion of blood volume [11]. This point was first demonstrated in 1961 in a classic paper by de Wardener and colleagues [12]. Natriuresis induced by saline infusion occurred even if renal perfusion pressure and glomerular filtration rate and aldosterone concentrations were prevented from changing. This so called 'third factor,' which we now understand is (are) CTS, was proposed by Bricker and colleagues to be an inhibitor of the Na/K-ATPase and, as such, produced natriuresis by inhibiting Na reabsorption in the kidney [13]. However, doubt as to the validity of circulating Na/K-ATPase inhibitors developed during the 1980s and 1990s because of inconsistencies in the reported results. In particular, prevailing CTS assays were based on cross-reactivity of CTS with antibodies to digoxin. The most

important inconsistency was that digitalis did not appear to be natriuretic in normal subjects, something one would expect in a candidate natriuretic substance [14]. Also, atrial (and brain) natriuretic peptide(s) were discovered and found to be natriuretic [15–19]. Undoubtedly, these points, detracted focus from the study of CTS. However, enthusiasm was renewed in the recent past for the following reasons. First, several CTS have been isolated from experimental animals and humans and chemically characterized. Specifically, marinobufagenin (MBG) as well as telecinobufagin (TCB) have been isolated from plasma and urine [20]. Ouabain has also been identified although there is still some debate as to whether this is ouabain or something distinct which also reacts to anti-ouabain antibodies [21•,22]. The concentrations of ouabain (or ouabain like compound) and MBG appear to be in the range of 2–30×10^{-10} M in humans, depending on whether disease is present [2,3,23]. Plasma levels of TCB and bufalin are less well defined at present.

Ionic model for Na/K-ATPase signaling

The concept proposed by Bricker and others was that third factor or cardiotonic steroids acted like digitalis and inhibited the enzymatic, ion pumping function of the Na/K-ATPase. The effects on sodium transport by the kidney seemed obvious in that clearly a failure to pump sodium out of epithelial cells would decrease net sodium reabsorption and effect natriuresis. Coupling the Na/K-ATPase to the Na/Ca exchanger, cardiac and smooth muscle relevance of these substances also seemed very clear in that subtle increases in cytosolic sodium would have amplified effects on cytosolic calcium, effecting changes in contractility in the heart as well as contractile tone in smooth muscle cells. The concept is illustrated in Figure 1.

Although we will explore an alternate hypothesis for the much of the remainder of this review, it must be said that this ionic model may explain some of the effects of digitalis and other cardiotonic steroids previously characterized as third factor. However, for reasons we will discuss below, certain discrepancies provoked scientists in our group, in particular Dr. Zijian Xie, to consider and elaborate a very different mechanism by which these cardiotonic steroids signal through the Na/K-ATPase.

Xie model of Na/K-ATPase signaling

The Xie model for the Na/K-ATPase signaling function was derived from difficulties explaining signaling with the ionic model along with experimental observations regarding reactive oxygen species (ROS) and tyrosine kinase activities being critical to such signaling. This model proposed that the caveolar Na/K-ATPase alpha1 subunit serves as a negative regulator of Src, and that during conformational changes in alpha1 induced by CTS or oxidation, Src is allowed to become active and trigger a signal cascade which involves the generation of reactive

Figure 1

A schematic illustrating the proposed ionic consequences of Na/K-ATPase inhibition. Note that such inhibition would predict increases in cytosolic sodium (Na^+) which, through Na/Ca exchange could increase cytosolic calcium (Ca^{2+}) concentration ([Ca^{2+}]). Decreases in cytosolic potassium (K^+) would change the membrane potential, favoring more Ca^{2+} entry, further increasing cytosolic [Ca^{2+}]. This would potentially activate phosphokinase C (PKC) and other Ca^{2+} dependent proteins, which in turn, would have a number of downstream effects.

oxygen species (ROS). This model is shown schematically in Figure 2, and in our admittedly biased opinion constitutes an important advance in our understanding of sodium pump signaling.

Problems with ionic model

Although the ionic model makes some predictions consistent with the observed pharmacology of Na/K-ATPase inhibitors, in general the concentrations of such inhibitors exceed by orders of magnitude those concentrations achieved in physiologically relevant models and clinical therapy. Although there is still some debate about this, it is generally accepted that endogenous cardiotonic steroids circulate at concentrations ranging from 10^{-10} to 10^{-8} M concentrations and pharmacologic treatment with digitalis compounds achieves concentrations of approximately 1–2×10^{-9} M [2]. In mice and rats used for many experiments, the IC50 for the $\alpha 1$ subunit approximates 10^{-5} M meaning that no detectable inhibition is seen with these lower concentrations. Even in humans which have a much more sensitive $\alpha 1$ subunit, the IC50 is approximately 10^{-7} M suggesting that these compounds might have relatively little effect. More importantly, changes in bulk cytosolic sodium are essentially impossible to detect with existing methods. Although these methods are not ideal and cannot identify sodium concentration changes in cytosolic subregions, it is still concerning. Perhaps of greater concern, sodium ionophores

Figure 2

A schematic illustrating the involvement of cardiotonic steroid (CTS)-induced Na/K-ATPase signal cascade initiated by the Na/K-ATPase mediated activation of Src tyrosine kinase and subsequent downstream targets eventually leading to the development of reactive oxygen species (ROS). Specifically, we postulate that in the microdomain of caveolae, the Na/K-ATPase functions as a scaffolding protein, interacting with CTS and changing conformation so as to active Src. Src then transactivates the EGFR which leads to a signal cascade involving FAK, Shc, Grb2 and SOS resulting in the generation of ROS which in turn activates additional Na/K-ATPase molecules as well as causes downstream activation of ERK as well as effects on the nuclear transcription [68]. ERK activation has effects on both L-type channels and possibly the Na/Ca exchanger with net effect to increase cytosolic Ca^{2+} in some tissues [35]. Nuclear effects in myocardial tissue include downregulation of SERCA transcription and translation [69]. *Abbreviations*: Epidermal growth factor receptor (EGFR); focal adhesion kinase (FAK); Src homology-2 domain containing protein (Shc); growth factor receptor-bound protein-2 (Grb2); son of sevenless protein (SOS); extracellular-signal-regulated kinase (ERK); sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA).

which can produce measurable changes in bulk cytosolic sodium do not appear to produce physiological changes similar to those produced by cardiotonic steroids [2,3].

Evidence for tyrosine kinase signaling

In the late 1990s, Dr. Xie and colleagues observed that in neonatal cardiac myocytes, ouabain caused increases in reactive oxygen species (ROS) measured with CMDCF [24]. These increases in ROS could be demonstrated even when cytosolic calcium was maintained low by removal of extracellular calcium [25]. It was further noted that some of the downstream effects of ouabain, specifically those on gene expression, calcium cycling and contractility could be blocked by N-Acetyl Cysteine (NAC) or vitamin E [24–26]. It was further noted that Ras activation appeared to be necessary to see increases in ROS [25]. Other studies determined that interactions between the Na/K-ATPase and Src appeared to initiate the signal cascade [27,28]. The α1 subunit of the Na/K-ATPase binds Src and appears to maintain it in an inactive state. However, binding a CTS appears to alter the Na/K-ATPase structure allowing Src

became activated which, in turn, trans-activates the EGFR, and begins the signal cascade which causes increases in ROS [27–30]. The Na/K-ATPase-Src complex appears to function similar to a receptor tyrosine kinase. Downstream activation of PLC, PI(3)K and PKC has also been established [31–35].

Some of our studies have shed light on the molecular basis of the Na/K-ATPase α1 subunit-Src interaction. It appears that there is a critical binding of the tyrosine kinase domain of Src by a portion of the N domain of the α1 subunit. Under basal conditions, this binding inhibits the tyrosine kinase function of Src. We speculate that conformational changes induced in the Na/K-ATPase by cardiotonic steroids and/or the specific oxidation of some amino-acids (vida infra) result in the internalization of this epitope and the disinhibition of the tyrosine kinase function of Src with attendant downstream signaling. This is illustrated in Figure 2. From this speculation, we have developed a peptide based on this epitope in combination with a tat leader sequence that allows for

cellular penetration which we refer to as pNaKtide. Although pNaKtide has no effect on Na/K-ATPase enzymatic or pumping function, it prevents a portion of Src activation which is usually regulated by the plamalemmal Na/K-ATPase [36,37].

Oxidant stress in chronic renal failure

Our group and others first proposed that oxidant stress contributed to the progression of chronic renal failure in the mid 1980s [38]. The concept which we proposed was that oxygen consumption by the chronic renal failure kidney could not be explained by the amount of tubular sodium transport performed in the setting of a reduced glomerular filtration rate. Patients with chronic renal failure consistently demonstrate elevations in circulating levels of oxidized proteins and byproducts of lipid peroxidation. This oxidant stress has been implicated in the pathogenesis of uremic cardiovascular disease on several levels [39].

A number of studies utilizing echocardiography have demonstrated that both left ventricular hypertrophy (LVH) and diastolic dysfunction (as assessed by left ventricular, atrial and pulmonary venous doppler flow studies) are extremely common in end stage renal disease (ESRD) patients treated with hemodialysis(HD) [40] as well as patients incident to ESRD [41–43]. In general, most studies have demonstrated that LVH predicts diastolic dysfunction with some accuracy. Systolic dysfunction while not uncommon is much less often demonstrable than diastolic dysfunction and LVH [44]. In experimental chronic renal failure, we have observed that left ventricular hypertrophy develops quite early and that impaired myocyte relaxation accompanies the cardiac enlargement. This impaired myocyte relaxation appears to be associated with a marked downregulation of SERCA2a mRNA, protein and activity. SERCA2a is the dominant isoform of the sarcoplasmic reticulum calcium ATPase and is responsible for the rapid reduction in cytosolic calcium following systole. We have found excellent correlations between the reduction in SERCA2a expression and SERCA enzymatic activity as well as calcium renormalization following electrical stimulation. We have also found marked abnormalities in cardiac myocyte calcium concentrations during both systole and diastole [26,45]. It is unclear at present whether the abnormalities in SERCA2a expression explain all of the changes in calcium cycling or active relaxation. Regarding passive relaxation, it is very clear that uremic cardiomyopathy is associated with profound cardiac fibrosis, both clinically and in both rats and mice with experimental renal failure [46•]. Our group has developed extensive evidence that blockade of Na/K-ATPase signaling results in amelioration of oxidant stress, downregulation of SERCA2a and cardiac fibrosis in these experimental uremic cardiomyopathy models [47–50].

Na/K-ATPase is a receptor for natriuretic hormones

Our group has identified that concentrations of CTS below that necessary to significantly inhibit the enzymatic function of the Na/K-ATPase directly induce endocytosis of the Na/K-ATPase in cell lines approximating proximal tubules, decreasing plasmalemmal Na/K-ATPase expression and function [51–53]. We have also found that this ligand-induced endocytosis appears to play a role in sodium homeostasis in intact animals [54]. We will discuss some of these mechanistic data below.

In renal proximal tubules, binding of CTS to Na/K-ATPase stimulates Na/K-ATPase-Src signaling pathway and reactive oxygen species (ROS) generation, which induces the redistribution of basalateral α1 subunit of Na/K-ATPase and apical sodium proton exchanger3 (NHE3). NHE3 (SLC9A3) is responsible for two-third of filtered sodium and fluid reabsorption as well as maintenance and regulation of intravascular volume and blood pressure [55–57]. Therefore, the downregulation of NHE3 will decrease transepithelial sodium transportation from apical membrane into basalateral membrane, leading to a net increase in urinary sodium excretion [25,52,58••,59–62].

We have begun to address the molecular basis of this regulation [63]. We have demonstrated that ouabain increases the carbonylation of α1 Na/K-ATPase in cultured porcine renal proximal tubular LLC-PK1 cells. A GO-glucose system was used to mimic overall ROS stress since GO induces a low and sustained generation of H_2O_2 in the presence of glucose in culture medium [24,25,64]. Like ouabain, the GO-generated ROS were able to activate Src/ERK and cause redistribution of the Na/K. Interestingly, the increase in intracellular ROS generated by the addition of glucose oxidase (GO) to the culture medium resulted in a nearly identical pattern of protein carbonylation to that seen with ouabain as well as what appears to be specific carbonylation of the α1 Na/K-ATPase. We have further identified that Pro222 and Thr224 residues of α1 Na/K-ATPase are specifically carbonylated in response to either exposure to ouabain or GO-generated ROS. Finally, using well-established animal models we have demonstrated that high salt intake is capable of eliciting this oxidative modification of the Na/K-ATPase as well as the associated signaling and salt handling events in the renal PT of Sprague Dawley rats and Dahl-salt resistant (R) but not Dahl salt-sensitive (S) rats [65]. Overall, our studies show that ROS are involved in CTS-mediated sodium handling through Na/K-ATPase signaling in a feed-forward mechanism [58••,66]. This is illustrated in Figure 3.

The implications of this feed-forward amplification are profound. One might think of the circulating CTS as the rheostat on an amplifier which promiscuously allows

Figure 3

Schematic showing the possible promiscuous consequences of feed forward oxidant amplification of the Na/K-ATPase. Here oxidants can be formed by receptor tyrosine kinases (RTK) or non-tyrosine kinase receptors (Non TK Receptor). Activation of the Na/K-ATPase signal cascade or RTK would activate the Ras-Raf-Rac-Nox pathway. As this leads to further generation of oxidants, a feed-forward pathway is thus established. We speculate that the endocytosis of the Na/K-ATPase (not shown on this schematic) which we discuss in the text terminates this feed-forward signal amplification.

oxidant signals from a variety of signal cascades to be amplified. This is clearly something which may be relevant beyond the circumstances discussed in this review. In fact, we have recently observed that the Na/K-ATPase amplification of such oxidant signals is essential for the development of an obesity phenotype, and the application of pNaKtide, a peptide we designed to bind the tyrosine kinase domain of Src based on the region of the Na/K-ATPase α1 subunit N domain which normally does so, dramatically attenuates this process [67••].

Conclusions

The recently discovered oxidant amplification function of the Na/K-ATPase appears relevant to a number of physiological and pathological processes including renal sodium handling and progressive cardiac fibrosis. Exploitation of this understanding may allow for modulation of such processes and the potential development of new clinical therapies.

Conflict of interest statement

Neither Dr. Yan or Dr. Shapiro have conflicts to report.

References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

- of special interest
- •• of outstanding interest

1. Skou JC: **The influence of some cations on an adenosine triphosphatase from peripheral nerves**. *Biochim Biophys Acta* 1957, **23**:394-401.

2. Bagrov AY, Shapiro JI, Fedorova OV: **Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets**. *Pharmacol Rev* 2009, **61**:9-38.

3. Bagrov AY, Shapiro JI: **Endogenous digitalis: pathophysiologic roles and therapeutic applications**. *Nat Clin Pract Nephrol* 2008, **4**:378-392.

4. Gable ME, Abdallah SL, Najjar SM, Liu L, Askari A: **Digitalis-induced cell signaling by the sodium pump: on the relation of Src to Na(+)/K(+)-ATPase**. *Biochem Biophys Res Commun* 2014, **446**:1151-1154.

5. Laursen M, Yatime L, Nissen P, Fedosova NU: **Crystal structure of the high-affinity Na+K+-ATPase–ouabain complex with Mg2+ bound in the cation binding site**. *Proc Natl Acad Sci U S A* 2013, **110**:10958-10963.

6. Geering K: **Functional roles of Na,K-ATPase subunits**. *Curr Opin Nephrol Hypertens* 2008, **17**:526-532.

7. Pavlovic D, Fuller W, Shattock MJ: **Novel regulation of cardiac Na pump via phospholemman**. *J Mol Cell Cardiol* 2013, **61**:83-93.

8. Nyblom M, Poulsen H, Gourdon P, Reinhard L, Andersson M,
• Lindahl E, Fedosova N, Nissen P: **Crystal structure of Na+, K(+)-ATPase in the Na(+)-bound state**. *Science* 2013, **342**:123-127.
The structure–function relations of the Na/K-ATPase have received new attention due to the recently recognized Na/K-ATPase signaling function. This study provides evidence showing that high-resolution structures will be essential for a better understanding of the structure-function relations of ion exchange, transport, and specificity and how the mechanism is affected by regulation and disease-related mutations.

9. Kanai R, Ogawa H, Vilsen B, Cornelius F, Toyoshima C: **Crystal structure of a Na+-bound Na+,K+-ATPase preceding the E1P state**. *Nature* 2013, **502**:201-206.

10. Esmann M, Fedosova NU, Olesen C: **Na,K-ATPase structure/function relationships probed by the denaturant urea**. *Biochim Biophys Acta* 2015, **1848**:1212-1223.

11. Abraham WT, Schrier RW: **Body fluid volume regulation in health and disease**. *Adv Intern Med* 1994, **39**:23-47.

12. de Wardener H, Mills IH, Clapham WF, Hayter CJ: **Studies on the efferent mechanism of the sodium diuresis which follows the administration of intravenous saline in the dog**. *Clin Sci* 1961, **21**:249-258.

13. Bricker NS, Klahr S, Lubowitz H, Slatopolsky E: **The pathophysiology of renal insufficiency. On the functional

transformations in the residual nephrons with advancing disease. *Pediatr Clin North Am* 1971, **18**:595-611.

14. Hauptman PJ, Kelly RA: **Digitalis**. *Circulation* 1999, **99**:1265-1270.

15. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H: **A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats**. *Life Sci* 1981, **28**:89-94.

16. de Bold AJ, Flynn TG: **Cardionatrin I — a novel heart peptide with potent diuretic and natriuretic properties**. *Life Sci* 1983, **33**:297-302.

17. Pamnani MB, Clough DL, Chen JS, Link WT, Haddy FJ: **Effects of rat atrial extract on sodium transport and blood pressure in the rat**. *Proc Soc Exp Biol Med* 1984, **176**:123-131.

18. Nakamoto M, Shapiro JI, Shanley PF, Chan L, Schrier RW: **In vitro and in vivo protective effect of atriopeptin III on ischemic acute renal failure**. *J Clin Invest* 1987, **80**:698-705.

19. Buckalew VM, Morris M, Hamilton RW: **Atrial natriuretic factor**. *Adv Intern Med* 1987, **32**:1-25.

20. Komiyama Y, Dong XH, Nishimura N, Masaki H, Yoshika M, Masuda M, Takahashi H: **A novel endogenous digitalis, telocinobufagin, exhibits elevated plasma levels in patients with terminal renal failure**. *Clin Biochem* 2005, **38**:36-45.

21. Baecher S, Kroiss M, Fassnacht M, Vogeser M: **No endogenous**
• **ouabain is detectable in human plasma by ultra-sensitive UPLC–MS/MS**. *Clin Chim Acta* 2014, **431**:
This study describes a novel method for measurement of ouabain in human plasma based on isotope dilution liquid chromatography tandem-mass spectrometry (ID-LC–MS/MS). Although the results show ouabain is not detected in human plasma with and without heart failure, this is in sharp contrast to all researchers based on immunoassay technology.

22. Hamlyn JM, Blaustein MP, Bova S, DuCharme DW, Harris DW, Mandel F, Mathews WR, Ludens JH: **Identification and characterization of a ouabain-like compound from human plasma**. *Proc Natl Acad Sci U S A* 1991, **88**:6259-6263.

23. Fedorova OV, Shapiro JI, Bagrov AY: **Endogenous cardiotonic steroids and salt-sensitive hypertension**. *Biochim Biophys Acta* 2010, **1802**:1230-1236.

24. Xie Z, Kometiani P, Liu J, Li J, Shapiro JI, Askari A: **Intracellular reactive oxygen species mediate the linkage of Na+/K+-ATPase to hypertrophy and its marker genes in cardiac myocytes**. *J Biol Chem* 1999, **274**:19323-19328.

25. Liu J, Tian J, Haas M, Shapiro JI, Askari A, Xie Z: **Ouabain interaction with cardiac Na+/K+-ATPase initiates signal cascades independent of changes in intracellular Na⁺ and Ca²⁺ concentrations**. *J Biol Chem* 2000, **275**:27838-27844.

26. Kennedy DJ, Vetteh S, Xie M, Periyasamy SM, Xie Z, Han C, Basrur V, Mutgi K, Fedorov V, Malhotra D, Shapiro JI: **Ouabain decreases sarco(endo)plasmic reticulum calcium ATPase activity in rat hearts by a process involving protein oxidation**. *Am J Physiol Heart Circ Physiol* 2006, **291**:H3003-H3011.

27. Haas M, Wang H, Tian J, Xie Z: **Src-mediated inter-receptor cross-talk between the Na+/K+-ATPase and the epidermal growth factor receptor relays the signal from ouabain to mitogen-activated protein kinases**. *J Biol Chem* 2002, **277**:18694-18702.

28. Haas M, Askari A, Xie Z: **Involvement of Src and epidermal growth factor receptor in the signal-transducing function of Na+/K+-ATPase**. *J Biol Chem* 2000, **275**:27832-27837.

29. Wang H, Haas M, Liang M, Cai T, Tian J, Li S, Xie Z: **Ouabain assembles signaling cascades through the caveolar Na+/K+-ATPase**. *J Biol Chem* 2004, **279**:17250-17259.

30. Tian J, Cai T, Yuan Z, Wang H, Liu L, Haas M, Maksimova E, Huang XY, Xie ZJ: **Binding of Src to Na+/K+-ATPase forms a functional signaling complex**. *Mol Biol Cell* 2006, **17**:317-326.

31. Elkareh J, Periyasamy SM, Shidyak A, Vetteth S, Schroeder J, Raju V, Hariri IM, El-Okdi N, Gupta S, Fedorova L, Liu J *et al.*: **Marinobufagenin induces increases in procollagen expression in a process involving protein kinase C and Fli-1: implications for uremic cardiomyopathy**. *Am J Physiol Renal Physiol* 2009, **296**:F1219-F1226.

32. Chen Y, Cai T, Yang C, Turner DA, Giovannucci DR, Xie Z: **Regulation of inositol 1,4,5-trisphosphate receptor-mediated calcium release by the Na/K-ATPase in cultured renal epithelial cells**. *J Biol Chem* 2008, **283**:1128-1136.

33. Pierre SV, Yang C, Yuan Z, Seminerio J, Mouas C, Garlid KD, Dos-Santos P, Xie Z: **Ouabain triggers preconditioning through activation of the Na+,K+-ATPase signaling cascade in rat hearts**. *Cardiovasc Res* 2007, **73**:488-496.

34. Yuan Z, Cai T, Tian J, Ivanov AV, Giovannucci DR, Xie Z: **Na/K-ATPase tethers phospholipase C and Ip3 receptor into a calcium-regulatory complex**. *Mol Biol Cell* 2005, **16**:4034-4045.

35. Tian J, Liu J, Garlid KD, Shapiro JI, Xie Z: **Involvement of mitogen-activated protein kinases and reactive oxygen species in the inotropic action of ouabain on cardiac myocytes. A potential role for mitochondrial K(ATP) channels**. *Mol Cell Biochem* 2003, **242**:181-187.

36. Li Z, Zhang Z, Xie JX, Li X, Tian J, Cai T, Cui H, Ding H, Shapiro JI, Xie Z: **Na/K-ATPase mimetic pNaKtide peptide inhibits the growth of human cancer cells**. *J Biol Chem* 2011, **286**:32394-32403.

37. Li Z, Cai T, Tian J, Xie JX, Zhao X, Liu L, Shapiro JI, Xie Z: **NaKtide, a Na/K-ATPase-derived peptide Src inhibitor, antagonizes ouabain-activated signal transduction in cultured cells**. *J Biol Chem* 2009, **284**:21066-21076.

38. Shapiro JI, Harris DC, Schrier RW, Chan L: **Attenuation of hypermetabolism in the remnant kidney by dietary phosphate restriction in the rat**. *Am J Physiol* 1990, **258**:F183-F188.

39. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: **The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia**. *Kidney Int* 2002, **62**:1524-1538.

40. Harnett JD, Parfrey PS, Griffiths SM, Gault MH, Barre P, Guttmann RD: **Left ventricular hypertrophy in end-stage renal disease**. *Nephron* 1988, **48**:107-115.

41. Stack AG, Saran R: **Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States**. *Am J Kidney Dis* 2002, **40**:1202-1210.

42. Mitsnefes MM, Daniels SR, Schwartz SM, Khoury P, Strife CF: **Changes in left ventricular mass in children and adolescents during chronic dialysis**. *Pediatr Nephrol* 2001, **16**:318-323.

43. Besarab A, Aslam M: **Should the hematocrit (hemoglobin) be normalized in pre-ESRD or dialysis patients? Yes!** *Blood Purif* 2001, **19**:168-174.

44. Raj DS, D'Mello S, Somiah S, Sheeba SD, Mani K: **Left ventricular morphology in chronic renal failure by echocardiography**. *Ren Fail* 1997, **19**:799-806.

45. Kennedy D, Omran E, Periyasamy SM, Nadoor J, Priyadarshi A, Willey JC, Malhotra D, Xie Z, Shapiro JI: **Effect of chronic renal failure on cardiac contractile function, calcium cycling, and gene expression of proteins important for calcium homeostasis in the rat**. *J Am Soc Nephrol* 2003, **14**:90-97.

46. Dial L, Liu J, Shapiro JI: **Cardiotonic steroids in adaptation to**
• **dietary salt intake**. *Curr Clin Pharmacol* 2014, **9**:298-309.
This review highlights the effects of the newly appreciated Na/K-ATPase signaling on renal proximal tubule mediated sodium handling, presenting a hypothesis for trade off between salt excretion and progressive CV disease.

47. Haller ST, Kennedy DJ, Shidyak A, Budny GV, Malhotra D, Fedorova OV, Shapiro JI, Bagrov AY: **Monoclonal antibody against marinobufagenin reverses cardiac fibrosis in rats with chronic renal failure**. *Am J Hypertens* 2012, **25**:690-696.

48. Kennedy DJ, Elkareh J, Shidyak A, Shapiro AP, Smaili S, Mutgi K, Gupta S, Tian J, Morgan E, Khouri S, Cooper CJ *et al.*: **Partial nephrectomy as a model for uremic cardiomyopathy in the mouse**. *Am J Physiol Renal Physiol* 2008, **294**:F450-F454.

49. Kennedy DJ, Vetteth S, Periyasamy SM, Kanj M, Fedorova L, Khouri S, Kahaleh MB, Xie Z, Malhotra D, Kolodkin NI, Lakatta EG *et al.*: **Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy**. *Hypertension* 2006, **47**:488-495.

50. Tian J, Shidyak A, Periyasamy SM, Haller S, Taleb M, El-Okdi N, Elkareh J, Gupta S, Gohara S, Fedorova OV, Cooper CJ *et al.*: **Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin**. *Hypertension* 2009, **54**:1313-1320.

51. Liu J, Liang M, Liu L, Malhotra D, Xie Z, Shapiro JI: **Ouabain-induced endocytosis of the plasmalemmal Na/K-ATPase in LLC-PK1 cells requires caveolin-1**. *Kidney Int* 2004, **66**:227-241.

52. Liu J, Kesiry R, Periyasamy SM, Malhotra D, Xie Z, Shapiro JI: **Ouabain induces endocytosis of plasmalemmal Na/K-ATPase in LLC-PK1 cells by a clathrin-dependent mechanism**. *Kidney Int* 2004, **66**:227-241.

53. Liu J, Periyasamy SM, Gunning W, Fedorova OV, Bagrov AY, Malhotra D, Xie Z, Shapiro JI: **Effects of cardiac glycosides on sodium pump expression and function in LLC-PK1 and MDCK cells**. *Kidney Int* 2002, **62**:2118-2125.

54. Periyasamy SM, Liu J, Tanta F, Kabak B, Wakefield B, Malhotra D, Kennedy DJ, Nadoor A, Fedorova OV, Gunning W, Xie Z *et al.*: **Salt loading induces redistribution of the plasmalemmal Na/K-ATPase in proximal tubule cells**. *Kidney Int* 2005, **67**:1868-1877.

55. Biemesderfer D, Pizzonia J, Abu-Alfa A, Exner M, Reilly R, Igarashi P, Aronson PS: **NHE3: a Na+/H+ exchanger isoform of renal brush border**. *Am J Physiol* 1993, **265**:F736-F742.

56. Alexander RT, Grinstein S: **Na+/H+ exchangers and the regulation of volume**. *Acta Physiol (Oxf)* 2006, **187**:159-167.

57. Amemiya M, Loffing J, Lotscher M, Kaissling B, Alpern RJ, Moe OW: **Expression of NHE-3 in the apical membrane of rat renal proximal tubule and thick ascending limb**. *Kidney Int* 1995, **48**:1206-1215.

58. Yan Y, Shapiro AP, Haller S, Katragadda V, Liu L, Tian J, Basrur V,
•• Malhotra D, Xie ZJ, Abraham NG, Shapiro JI *et al.*: **Involvement of reactive oxygen species in a feed-forward mechanism of Na/K-ATPase-mediated signaling transduction**. *J Biol Chem* 2013, **288**:34249-34258.
The binding of cardiotonic steroids to Na/K-ATPase inhibits renal proximal tubule sodium reabsorption and increases urinary sodium excretion, contributing to blood pressure regulation. This study is notable for the novel finding of reactive oxygen species are involved this process in a feed-forward mechanism, suggesting that the Na/K-ATPase can act as a receptor for some reactive oxygen species and potentially serve as a feed-forward amplifier.

59. Liu J, Xie ZJ: **The sodium pump and cardiotonic steroids-induced signal transduction protein kinases and calcium-signaling microdomain in regulation of transporter trafficking**. *Biochim Biophys Acta* 2010, **1802**:1237-1245.

60. Liu J, Shapiro JI: **Regulation of sodium pump endocytosis by cardiotonic steroids: molecular mechanisms and physiological implications**. *Pathophysiology* 2007, **14**:171-181.

61. Yan Y, Haller S, Shapiro A, Malhotra N, Tian J, Xie Z, Malhotra D, Shapiro JI, Liu J: **Ouabain-stimulated trafficking regulation of the Na/K-ATPase and NHE3 in renal proximal tubule cells**. *Mol Cell Biochem* 2012, **367**:175-183.

62. Liu J, Yan Y, Liu L, Xie Z, Malhotra D, Joe B, Shapiro JI: **Impairment of Na/K-ATPase signaling in renal proximal tubule contributes to DAHL salt-sensitive hypertension**. *J Biol Chem* 2012, **286**:22806-22813.

63. Yan Y, Shapiro AP, Haller S, Katragadda V, Liu L, Tian J, Basrur V, Malhotra D, Xie Z-j, Abraham NG, Shapiro JI *et al.*: **Involvement of reactive oxygen species in a feed-forward mechanism of Na/K-ATPase-mediated signaling transduction**. *J Biol Chem* 2013, **288**:34249-34258.

64. Liu L, Li J, Liu J, Yuan Z, Pierre SV, Qu W, Zhao X, Xie Z: **Involvement of Na+/K+-ATPase in hydrogen peroxide-induced hypertrophy in cardiac myocytes**. *Free Radic Biol Med* 2006, **41**:1548-1556.

65. Liu J, Yan Y, Liu L, Xie Z, Malhotra D, Joe B, Shapiro JI: **Impairment of Na/K-ATPase signaling in renal proximal tubule contributes to Dahl salt-sensitive hypertension**. *J Biol Chem* 2011, **286**:22806-22813.

66. Liu J, Kennedy DJ, Yan Y, Shapiro JI: **Reactive oxygen species modulation of Na/K-ATPase regulates fibrosis and renal proximal tubular sodium handling**. *Int J Nephrol* 2012 http://dx.doi.org/10.1155/2012/383120.

67. Sodhi K, Mawell K, Yan Y, Liu J, Chaudhry MA, Getty M, Xie Z,
•• Abraham NG, Shapiro JI: **pNaKtide inhibits Na/K-ATPase reactive oxygen species amplification and attenuate adipogenesis**. *Sci Adv* 2015, **1**:e1500781.
This study demonstrates that the Na/K-ATPase signal cascade can serve as a feed-forward amplifier for oxidant signaling in the context of adipogenesis. This study is notable for the novel finding that pNaKtide, a protein developed to terminate Na/K-ATPase signaling can attenuate adipogenesis caused by a variety of stimuli *in vitro* and *in vivo*.

68. Pierre SV, Xie Z: **The Na,K-ATPase receptor complex: its organization and membership**. *Cell Biochem Biophys* 2006, **46**:303-316.

69. Kennedy DJ, Malhotra D, Shapiro JI: **Molecular insights into uremic cardiomyopathy: cardiotonic steroids and Na/K ATPase signaling**. *Cell Mol Biol (Noisy-le-grand)* 2006, **52**:3-14.